Literature DB >> 28607019

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.

S M Stainton1, M L Monogue1, D P Nicolau2,3.   

Abstract

Recent findings have identified Klebsiella pneumoniae strains that are pan-β-lactam susceptible (PBL-S) but piperacillin-tazobactam resistant (TZP-R) in vitro We assessed the efficacy of a humanized exposure of piperacillin-tazobactam (TZP) against 12 TZP-R/PBL-S K. pneumoniae isolates in an immunocompromised murine lung infection model. Discordance between the in vitro resistance profile and the in vivo efficacy of human-simulated TZP exposures against this phenotypic profile was observed. Additional studies are required to define the clinical implications of these TZP-R/PBL-S strains.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Klebsiella pneumoniae; antibiotic resistance; piperacillin-tazobactam

Mesh：

Substances：

Year:  2017        PMID： 28607019      PMCID： PMC5487623          DOI： 10.1128/AAC.00491-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Authors:  Catharine C Bulik; Pamela R Tessier; Rebecca A Keel; Christina A Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

4.  Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Catharine C Bulik; Henry Christensen; Peng Li; Christina A Sutherland; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

5.  Impact of blaNDM-1 on fitness and pathogenicity of Escherichia coli and Klebsiella pneumoniae.

Authors:  Stephan Göttig; Sara Riedel-Christ; Ahmad Saleh; Volkhard A J Kempf; Axel Hamprecht
Journal:  Int J Antimicrob Agents       Date:  2016-04-26       Impact factor: 5.283

Review 6.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

7.  Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.

Authors:  Christina A Sutherland; David P Nicolau
Journal:  Clin Ther       Date:  2015-06-15       Impact factor: 3.393

8.  In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

9.  Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Virna J Schuck; Mary Anne Banevicius; Marie-Eve Beaudoin; Wright W Nichols; M Angela Tanudra; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

10.  Inhibition of the renal excretion of tazobactam by piperacillin.

Authors:  M Komuro; T Maeda; H Kakuo; H Matsushita; J Shimada
Journal:  J Antimicrob Chemother       Date:  1994-10       Impact factor: 5.790
View more
  5 in total

1.  Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.

Authors:  Sean M Stainton; Kamilia Abdelraouf; Luke Utley; Michael J Pucci; Troy Lister; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Authors:  Lindsay M Avery; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

3.  Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.

Authors:  Thomas M Baker; Wesley Rogers; Kalyan D Chavda; Lars F Westblade; Stephen G Jenkins; David P Nicolau; Barry N Kreiswirth; David P Calfee; Michael J Satlin
Journal:  Open Forum Infect Dis       Date:  2018-11-19       Impact factor: 3.835

4.  Piperacillin/tazobactam-resistant, cephalosporin-susceptible Escherichia coli bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types.

Authors:  Thomas Edwards; Eva Heinz; Jon van Aartsen; Alex Howard; Paul Roberts; Caroline Corless; Alice J Fraser; Christopher T Williams; Issra Bulgasim; Luis E Cuevas; Christopher M Parry; Adam P Roberts; Emily R Adams; Jenifer Mason; Alasdair T M Hubbard
Journal:  Microb Genom       Date:  2022-04

5.  Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.

Authors:  Lisa M Schechter; David P Creely; Cherilyn D Garner; Dee Shortridge; Hoan Nguyen; Lei Chen; Blake M Hanson; Erica Sodergren; George M Weinstock; W Michael Dunne; Alex van Belkum; Shana R Leopold
Journal:  MBio       Date:  2018-04-24       Impact factor: 7.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.